DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

Information source: Henry M. Jackson Foundation for the Advancement of Military Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Post-traumatic Headache

Intervention: Rizatriptan (Drug); Placebo (Drug)

Phase: N/A

Status: Withdrawn

Sponsored by: Henry M. Jackson Foundation for the Advancement of Military Medicine

Official(s) and/or principal investigator(s):
Jay C Erickson, MD, Principal Investigator, Affiliation: U.S. Army Medical Corp. Madigan Army Medical Center


The purpose of the study is to determine the effectiveness of rizatriptan for treating attacks of chronic post-traumatic headache.

Clinical Details

Official title: A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Rizatriptan 10 mg Oral Disintegrating Tablet for Treatment of Acute Attacks of Chronic, Blast-induced, Post-traumatic Headache in U.S. Military Troops

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Headache Severity

Secondary outcome: 24 hour Migraine Quality of Life score

Detailed description: Chronic post-traumatic headaches develop in about one third of soliders who have had head trauma caused by a blast. A wide variety of pain medicines, including rizatriptan, are used to treat these headaches in clinical practice. However, the effectiveness has not been established by clinical research studies.


Minimum age: 18 Years. Maximum age: 49 Years. Gender(s): Male.


Inclusion Criteria: 1. U. S. Army soldier with history of concussion while deployed to a combat zone. Concussion is defined as head trauma with all of the following: 2. No loss of consciousness or loss of consciousness less than 30 minutes. 3. Glasgow Coma Score 13-15 (if known) 4. Symptoms or signs of concussion. 5. Concussion was secondary to primary, secondary, or tertiary blast injury. 6. Headaches started within 7 days of concussion. 7. Headaches have occurred for more than 3 months but not more than 24 months since the precipitating concussion. 8. Headaches occurred 3 to 14 days per month during each of the previous two months. 9. Headaches are migraine type and possess three or more of the following migraine features: 10. moderate or severe pain 11. throbbing or pulsatile pain 12. unilateral or asymmetric pain 13. pain exacerbated by or interfering with routine physical activity 14. nausea or vomiting 15. photosensitivity and phonosensitivity 16. Headaches last 4 or more hours without treatment. 17. Males 18 to 49 years of age. 18. Migraine Disability Assessment Score (MIDAS) greater than 10 or Headache Impact Test-6 (HIT6) score greater than 60.


Exclusion Criteria: 1. Patients with a history of migraine headaches prior to concussion will be excluded. 2. Prior use of any triptan medication for headache. 3. Use of non-opioid analgesic medications 15 or more days per month for the previous month. 4. Use of opioid medications more than 10 days in the previous month. 5. Alcohol consumption of more than two servings (a serving is 2 oz hard liquor, 5 oz wine, or 12 oz beer) per day or more than 3 servings at one time on a weekly basis. 6. Taking two or more medications from the following medication classes: SSRI, SNRI, or TCA. 7. Headache prophylactic medication is allowed but must remain unchanged during the study period. 8. Patients with depression, defined as a PHQ-9 score greater than 15, will be excluded from study participation. 9. PTSD is NOT an exclusion criterion. PTSD will be defined as a clinical diagnosis by a behavioral health provider or PTSD symptom checklist score of 50 or higher. 10. Systolic BP > 140 or diastolic BP > 90 on repeated measurements. 11. Active use of dihydroergotamine. 12. Known coronary artery disease, prior myocardial infarction, history of stroke or TIA, or liver disease. 13. Subjects who will not be available for study-related follow-up visits will be excluded. 14. Patient has cognitive impairment defined as mini-mental status exam score less than 27. 15. Patients undergoing a medical board for headache, sequelae of TBI, or psychiatric disorders will be excluded. 16. Patients suspected of malingering, exaggerating symptoms, or non-compliance will be excluded from study participation. 17. Patient has hemiplegic migraine or basilar migraine.

Locations and Contacts

Madigan Army Medical Center - Neurology Clinic, Tacoma, Washington 98431, United States
Additional Information

Starting date: February 2011
Last updated: August 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017